BD Acquires Tissuemed, Ltd. To Add Advanced Sealant To Its Portfolio Of Surgical Solutions

- Acquisition complements BD's core portfolio - adding an innovative, broadly applicable surgical sealant to a suite of BD biosurgery products already relied upon in the operating room.

- Integration will enable BD to further build on Tissuemed's strong foundation in sealant technology, a category that is growing significantly across the globe.

FRANKLIN LAKES, N.J., Dec. 9, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired Tissuemed, Ltd., a privately held firm headquartered in Leeds, England that is an industry leader in developing self-adhesive surgical sealant films.

The acquisition of Tissuemed, Ltd. expands BD's global offerings for surgeons outside of the United States. Tissuemed's lead product, Tissuepatch, is a proprietary sealant technology that bonds to tissue to help control internal bleeding or prevent leaks from surgical incisions. The technology's thin, flexible and transparent composition that is ready to use out of the package makes it ideally suited for a range of surgical sealant applications.

"This advanced sealant serves as a strategic complement to the BD products used in the operating room today — providing us with the opportunity to equip surgeons with a more robust, highly-integrated portfolio of surgical solutions," said Kevin Kelly, president of Surgery for BD. "Integrating Tissuepatch into our business aligns with our commitment to continuously innovate in our core portfolio to help support minimally invasive surgeries." 

Tissuepatch is already trusted among surgeons due to its design, which enables strong adhesive and minimal swelling. This foundation provides BD with an opportunity to leverage its reach and clinical expertise to continue to innovate within the sealant technology category, which is expected to grow significantly over the next five to 10 years.

Terms of the transaction were not disclosed. The transaction is expected to be immaterial to BD's fiscal 2022 financial results.

About BD 
BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at and Twitter @BDandCo.


Trey Hollern                  

BD Public Relations



Nadia Goncalves

BD Investor Relations


Cision View original content to download multimedia:

SOURCE BD (Becton, Dickinson and Company)